Ginsenoside Rg1 alleviates PTSD-like sleep disturbances in male mice by modulating NLRP3 inflammation and apoptosis
Background
Post-traumatic stress disorder (PTSD) is characterized by debilitating symptoms, with sleep disturbances (SD) being a critical component that not only manifests as a symptom but also exacerbates and perpetuates other PTSD phenotypes. Current treatments often fall short in comprehensively addressing both the behavioral and underlying neurobiological aspects of PTSD-SD. Shared mechanisms with neurodegenerative diseases like oxidative stress, chronic inflammation, and neurodegeneration highlight the need for interventions targeting these pathways. Ginsenoside Rg1, known for its applications in neuropsychiatric conditions, presents a promising candidate to modulate these complex interactions and improve PTSD-related sleep issues.
Study Design
Researchers established a PTSD model in male mice using single-prolonged stress (SPS) to induce PTSD-like behaviors and sleep disturbances. Following SPS, mice were administered Ginsenoside Rg1 (dose, route, and frequency not specified in abstract). The study assessed the improvement effect of Ginsenoside Rg1 on PTSD-like behaviors, specifically focusing on the sleep-wake phase. Bioinformatics analysis was employed to predict potential targets and signaling pathways for Ginsenoside Rg1 in treating PTSD-SD. These predictions were subsequently verified through in vivo experiments, examining markers in the hippocampus.
Results
The SPS model successfully induced significant sleep architecture disturbances in mice 14 days after the stress event. Administration of Ginsenoside Rg1 effectively treated these PTSD-like sleep disturbances in the SPS mice. Bioinformatics analysis strongly suggested that NLRP3-related pathways and apoptosis were key factors in Ginsenoside Rg1's therapeutic action against PTSD-like sleep disturbances. Animal experiments further corroborated these findings: hippocampal expression of NLRP3 inflammasome, oxidative stress, and apoptosis-related markers were abnormally elevated in SPS mice. However, Ginsenoside Rg1 administration counteracted this dysregulated expression, restoring levels towards normal. > Docking studies revealed that Ginsenoside Rg1 exhibited favorable binding affinity with verified targets including NF-κB, NLRP3, ASC, GFAP, HO-1, and cleaved caspase-3, indicating direct molecular interactions.
Key Findings
- SPS model induced significant sleep architecture disturbances in male mice.
- Ginsenoside Rg1 treatment improved PTSD-like sleep disturbances in SPS mice.
- Bioinformatics predicted
NLRP3-related pathways and apoptosis as key targets for Rg1. - Rg1 counteracted dysregulated hippocampal
NLRP3 inflammasome, oxidative stress, and apoptosis markers in SPS mice. - Ginsenoside Rg1 showed favorable binding affinity to
NF-κB,NLRP3,ASC,GFAP,HO-1, andcleaved caspase-3.
Why It Matters
This research suggests Ginsenoside Rg1 could be a novel therapeutic agent for PTSD-related sleep disturbances, offering a potential strategy beyond conventional pharmacotherapies. By targeting the underlying NLRP3 inflammasome activation, oxidative stress, and apoptosis, Ginsenoside Rg1 addresses core neurobiological mechanisms implicated in PTSD pathology. This opens avenues for exploring Ginsenoside Rg1 as a complementary or alternative approach to improve sleep quality and overall PTSD symptoms. While promising, the lack of specific dosing protocols in this preclinical study means further research is needed to translate these findings into human-applicable protocols or stacks, including optimal dose, route, and duration.
ginsenoside rg1
ptsd
sleep disturbances
inflammation
apoptosis
nlrp3